About
Azitra is a clinical-stage biopharmaceutical company developing precision dermatology therapies using engineered strains of S. epidermidis. Its lead program, ATR-12, is in a Phase 1b trial for Netherton syndrome, a rare and life-threatening skin disease with no approved treatments. Azitra is also advancing ATR-04, currently in a Phase 1/2 trial, to treat EGFR inhibitor–associated skin toxicity, a condition affecting roughly 150,000 people in the U.S. Supported by a proprietary platform of engineered proteins, live biotherapeutics, and an AI-enhanced microbial library of 1,500 strains, Azitra is pioneering targeted, innovative solutions for severe dermatologic needs.
Branford